Naureen Quibria
Stock Analyst at Capital One
(0)
# 5154
Out of 5,370 analysts
15
Total ratings
12.50%
Success rate
-39.57%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
BMEA Biomea Fusion | Initiates Coverage On: Overweight | 25 | 2.65 | 843.4% | 1 | Aug 29, 2024 | |
IMMP Immutep | Initiates Coverage On: Overweight | 10 | 1.71 | 484.8% | 1 | May 17, 2024 | |
ERAS Erasca | Initiates Coverage On: Overweight | 8 | 1.41 | 467.38% | 1 | Mar 11, 2024 | |
CARM CARISMA Therapeutics | Initiates Coverage On: Overweight | 10 | n/a | n/a | 1 | Oct 3, 2023 | |
IMCR Immunocore Hldgs | Initiates Coverage On: Overweight | 84 | 32.63 | 157.43% | 1 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | n/a | n/a | n/a | 2 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 6.64 | 502.41% | 1 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 11 | 8.08 | 36.14% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | n/a | n/a | 2 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 21 | 3.53 | 494.9% | 1 | Jan 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 22 | n/a | n/a | 1 | Dec 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 900 | 9.2 | 9682.61% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 35 | n/a | n/a | 1 | Mar 16, 2021 |